Changeflow GovPing Healthcare & Life Sciences Anti-Sortilin Antibodies for Use in Therapy by ...
Routine Rule Added Final

Anti-Sortilin Antibodies for Use in Therapy by Alector LLC

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3983441A1 for Alector LLC, covering anti-sortilin antibodies for therapeutic use in neurological conditions. The application was published April 15, 2026 under IPC classification C07K 16/28 (peptides, antibodies) with designations across 35 European states. Inventors include Robert Paul, Michael F. Ward, Hua Long, Shiao-Ping Lu, Omer Rizwan Siddiqui, Arnon Rosenthal, and Herve Rhinn.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.

What changed

The EPO published patent application EP3983441A1 for anti-sortilin antibodies for use in therapy, filed by Alector LLC. The application covers therapeutic applications in neurological conditions including Alzheimer's disease and related dementias, as indicated by classification A61P 25/28.

For companies developing sortilin-targeted biologics or neuroprotective therapies, this publication signals potential freedom-to-operate considerations in European markets. Competitors should review the patent's claims upon grant to assess potential licensing needs or design-around options.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

ANTI-SORTILIN ANTIBODIES FOR USE IN THERAPY

Publication EP3983441A1 Kind: A1 Apr 15, 2026

Applicants

Alector LLC

Inventors

PAUL, Robert, WARD, Michael F., LONG, Hua, LU, Shiao-Ping, SIDDIQUI, Omer Rizwan, ROSENTHAL, Arnon, RHINN, Herve

IPC Classifications

C07K 16/28 20060101AFI20201218BHEP G01N 33/53 20060101ALI20201218BHEP A61P 25/28 20060101ALI20201218BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3983441A1

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies Research institutions
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent publication Biologic therapeutics Antibody development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Biotechnology

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!